Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys

Vaccine
Tong-Ming FuJoseph G Joyce

Abstract

Immunization against M2 peptide, also called M2e, from influenza A virus is an innovative vaccine approach for induction of cross-strain protective immunity. Two promising M2 vaccine compositions reported to date are M2 peptide chemically conjugated to carrier proteins or M2 peptide recombinantly expressed on the surface of virus like particles (VLPs) of hepatitis B virus core antigen (HBVc). To conduct a head-to-head comparison of these approaches, we constructed two recombinant HBVc VLPs expressing M2 peptide and prepared two conjugate vaccines with M2 peptide chemically coupled to Neisseria meningitidis outer membrane complex (OMPC) or HBVc VLP, respectively. Here, we showed superior immunogenicity of M2 peptide conjugated to OMPC and M2 peptide expressed on the surface of HBVc antigen based on dose-titration responses in mice. Surprisingly, HBVc expressing M2 peptide was an inferior vaccine in rhesus monkeys, whether as a primary vaccine or as a booster vaccine, when compared with M2-OMPC conjugate vaccine.

References

Apr 1, 1978·Proceedings of the National Academy of Sciences of the United States of America·A HinnenG R Fink
Dec 8, 1992·Journal of Immunological Methods·K R ShulerP Kanda
May 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M A LiuL A Hawe
Mar 1, 1992·Virus Research·F CiamporA J Hay
Jan 1, 1993·The Journal of General Virology·R A BlackA P Kendal
Mar 1, 1996·The Journal of Experimental Medicine·L M WetzlerL W Wetzler
May 13, 1997·Proceedings of the National Academy of Sciences of the United States of America·T SakaguchiR A Lamb
Apr 1, 1997·Journal of Structural Biology·R Bringas
Feb 7, 1998·Proceedings of the National Academy of Sciences of the United States of America·D R MilichJ L Hughes
Mar 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·P A KratzM Nassal
Jul 8, 1999·Molecular Cell·S A WynneA G Leslie
Aug 7, 1999·The Journal of Infectious Diseases·F G MackinnonL M Wetzler
Apr 25, 2000·Annual Review of Medicine·N J Cox, K Subbarao
Dec 15, 2000·The New England Journal of Medicine·R B Couch
Aug 18, 2001·Intervirology·P Pumpens, E Grens
Dec 12, 2001·Vaccine·S L Morley, A J Pollard
May 4, 2002·Biochimica Et Biophysica Acta·Wolfgang B Fischer, Mark S P Sansom
Mar 12, 2003·FEMS Immunology and Medical Microbiology·Wanli LiuYing-Hua Chen
May 26, 2005·Virology·Marina De FiletteWalter Fiers
Nov 30, 2005·Journal of Pharmaceutical Sciences·Roxana M IonescuLi Shi
Jan 18, 2008·The New England Journal of Medicine·UNKNOWN Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian InfTimothy M Uyeki
Feb 5, 2008·Vaccine·Dubravka Grdic EliassonNils Lycke
Feb 7, 2008·The Journal of Biological Chemistry·Marina De FiletteXavier Saelens

❮ Previous
Next ❯

Citations

Dec 12, 2013·The Journal of Infectious Diseases·Weimin ZhongUNKNOWN Influenza Serology Working Group
Mar 5, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Min-Chul KimSang-Moo Kang
Dec 29, 2010·Proceedings of the National Academy of Sciences of the United States of America·Jae-Min SongSang-Moo Kang
Nov 18, 2010·Virus Genes·Seyyed Mahmoud Ebrahimi, Majid Tebianian
May 21, 2013·Trends in Microbiology·Kanta Subbarao, Yumiko Matsuoka
Dec 19, 2012·Molecular Therapy : the Journal of the American Society of Gene Therapy·Min-Chul KimSang-Moo Kang
Jun 8, 2011·Immunology and Cell Biology·Garry W LynchJohn S Sullivan
Sep 26, 2012·Expert Review of Vaccines·Alan R Shaw
Sep 26, 2012·Expert Review of Vaccines·Sang-Moo KangRichard W Compans
Oct 30, 2009·Expert Review of Vaccines·David C WhitacreDavid R Milich
Sep 8, 2015·Vaccines·Lei DengXavier Saelens
May 11, 2013·Expert Review of Vaccines·Adrian Reber, Jacqueline Katz
Nov 12, 2015·Immune Network·Yu-Na LeeSang-Moo Kang
Oct 5, 2011·Virus Research·S M KangR W Compans
Jan 19, 2010·Microbes and Infection·Lanying DuShibo Jiang
Apr 26, 2012·European Journal of Immunology·Nicole SchmitzMartin F Bachmann
Apr 3, 2016·Vaccine·Francesco Berlanda ScorzaJohn J Donnelly
Nov 27, 2014·Human Vaccines & Immunotherapeutics·Cécile van ElsFredrik Oftung
Mar 26, 2014·Current Opinion in Virology·Ming Tan, Xi Jiang
Jan 16, 2014·Clinical and Experimental Vaccine Research·Young-Tae LeeSang-Moo Kang
Jul 10, 2010·Proceedings of the National Academy of Sciences of the United States of America·Andres G GrandeaMatthew Moyle
Oct 8, 2013·PloS One·Denis LeclercPierre Savard
Sep 23, 2016·Expert Review of Vaccines·Annasaheb KolpeXavier Saelens

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.